Histone Deacetylase Inhibitors

"Histone Deacetylase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Compounds that inhibit HISTONE DEACETYLASES. This class of drugs may influence gene expression by increasing the level of acetylated HISTONES in specific CHROMATIN domains.

Descriptor ID	D056572
MeSH Number(s)	D27.505.519.389.360
Concept/Terms	Histone Deacetylase Inhibitors Histone Deacetylase Inhibitors Deacetylase Inhibitors, Histone Inhibitors, Histone Deacetylase Histone Deacetylase Inhibitor Deacetylase Inhibitor, Histone Inhibitor, Histone Deacetylase HDAC Inhibitors Inhibitors, HDAC

Below are MeSH descriptors whose meaning is more general than "Histone Deacetylase Inhibitors".

Chemicals and Drugs [D]
Chemical Actions and Uses [D27]
Pharmacologic Actions [D27.505]
Molecular Mechanisms of Pharmacological Action [D27.505.519]
Enzyme Inhibitors [D27.505.519.389]
Histone Deacetylase Inhibitors [D27.505.519.389.360]

Below are MeSH descriptors whose meaning is related to "Histone Deacetylase Inhibitors".

Below are MeSH descriptors whose meaning is more specific than "Histone Deacetylase Inhibitors".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Histone Deacetylase Inhibitors" by people in this website by year, and whether "Histone Deacetylase Inhibitors" was a major or minor topic of these publications.

Bar chart showing 47 publications over 18 distinct years, with a maximum of 6 publications in 2010

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2001	0	1	1
2002	1	0	1
2003	0	1	1
2004	2	1	3
2005	3	0	3
2006	0	1	1
2007	1	2	3
2008	4	1	5
2009	2	2	4
2010	1	5	6
2011	3	1	4
2013	1	1	2
2014	0	2	2
2015	3	0	3
2016	0	2	2
2017	0	3	3
2018	1	1	2
2021	1	0	1

Below are the most recent publications written about "Histone Deacetylase Inhibitors" by people in Profiles.

Pitt B, Sutton NR, Wang Z, Goonewardena SN, Holinstat M. Potential repurposing of the HDAC inhibitor valproic acid for patients with COVID-19. Eur J Pharmacol. 2021 May 05; 898:173988.

View in: PubMed
Marcotte JH, Rattigan DA, Irons RF, Cahill KW, Zhang P, Chang S, Koko KR, Gaughan JP, Carpenter JP, Brown SA, Budak-Alpdogan T. The Effect of the Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid and Paclitaxel Treatment on Full-Thickness Wound Healing in Mice. Ann Plast Surg. 2018 10; 81(4):482-486.

View in: PubMed
Fan CW, Yarravarapu N, Shi H, Kulak O, Kim J, Chen C, Lum L. A synthetic combinatorial approach to disabling deviant Hedgehog signaling. Sci Rep. 2018 01 18; 8(1):1133.

View in: PubMed
Roman J, Zhu J, Ritzenthaler JD, Zelko IN. Epigenetic regulation of EC-SOD expression in aging lung fibroblasts: Role of histone acetylation. Free Radic Biol Med. 2017 11; 112:212-223.

View in: PubMed
Hu ZI, Ho AY, McArthur HL. Combined Radiation Therapy and Immune Checkpoint Blockade Therapy for Breast Cancer. Int J Radiat Oncol Biol Phys. 2017 09 01; 99(1):153-164.

View in: PubMed
Quagliano A, Gopalakrishnapillai A, Barwe SP. Epigenetic drug combination overcomes osteoblast-induced chemoprotection in pediatric acute lymphoid leukemia. Leuk Res. 2017 05; 56:36-43.

View in: PubMed
Mishra A, La Perle K, Kwiatkowski S, Sullivan LA, Sams GH, Johns J, Curphey DP, Wen J, McConnell K, Qi J, Wong H, Russo G, Zhang J, Marcucci G, Bradner JE, Porcu P, Caligiuri MA. Mechanism, Consequences, and Therapeutic Targeting of Abnormal IL15 Signaling in Cutaneous T-cell Lymphoma. Cancer Discov. 2016 Sep; 6(9):986-1005.

View in: PubMed
Butchbach MER, Lumpkin CJ, Harris AW, Saieva L, Edwards JD, Workman E, Simard LR, Pellizzoni L, Burghes AHM. Protective effects of butyrate-based compounds on a mouse model for spinal muscular atrophy. Exp Neurol. 2016 May; 279:13-26.

View in: PubMed
Adams CM, Hiebert SW, Eischen CM. Myc Induces miRNA-Mediated Apoptosis in Response to HDAC Inhibition in Hematologic Malignancies. Cancer Res. 2016 Feb 1; 76(3):736-48.

View in: PubMed
Sampson VB, Vetter NS, Kamara DF, Collier AB, Gresh RC, Kolb EA. Vorinostat Enhances Cytotoxicity of SN-38 and Temozolomide in Ewing Sarcoma Cells and Activates STAT3/AKT/MAPK Pathways. PLoS One. 2015; 10(11):e0142704.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement